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Abstract
Muscle contractile proteins are expressed as a series of developmental isoforms that are in constant dynamic remodeling
during embryogenesis, but how obsolete molecules are recognized and removed is not known. Ozz is a developmentally
regulated protein that functions as the adaptor component of a RING-type ubiquitin ligase complex specific to striated
muscle. Ozz
2/2 mutants exhibit defects in myofibrillogenesis and myofiber differentiation. Here we show that Ozz targets
the rod portion of embryonic myosin heavy chain and preferentially recognizes the sarcomeric rather than the soluble pool
of myosin. We present evidence that Ozz binding to the embryonic myosin isoform within sarcomeric thick filaments marks
it for ubiquitination and proteolytic degradation, allowing its replacement with neonatal or adult isoforms. This unique
function positions Ozz within a system that facilitates sarcomeric myosin remodeling during muscle maturation and
regeneration. Our findings identify Ozz-E3 as the ubiquitin ligase complex that interacts with and regulates myosin within its
fully assembled cytoskeletal structure.
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Introduction
Striated muscle cells exhibit the paradoxical association of a
rigidly ordered fine structure with the ability to adapt their size and
contractile properties during growth and development, or in
response to changes in their patterns of use. Many sarcomeric
proteins are developmentally expressed as a series of isoforms
leading at maturation to patterns appropriate for slow or fast
contraction, and aerobic or anaerobic metabolism. Accordingly,
mechanisms must exist to enable replacement of isoforms while
maintaining an almost crystalline regularity of structural pattern.
The classic suggestion of how such mechanisms may operate is
based on in vitro experiments where myosin monomers spontane-
ously polymerize to reach a dynamic equilibrium between fully
polymerized myosin and a small pool of soluble monomers [1].
However, in a theoretical study, Davis concluded that a model
based on kinetic parameters could not account for the rapid
replacementofonemyosinisoformbyanotherthat isseen invivo[2].
The ubiquitin-proteasome system [3–5] is the prime candidate
for targeted degradation of most soluble and myofibrillar proteins.
In skeletal muscles, ubiquitination of muscle proteins to target
them for proteolysis is an important component of cachexia and
muscle atrophy [6,7]. Evidence for ubiquitin-mediated degrada-
tion of myosin is mostly indirect, but the E3 ubiquitin ligases
MuRF1, which is induced during muscle atrophy, and MuRF3
mediate the ubiquitination of soluble myosin in vitro [8,9], binding
to multiple sites near the head region of MyHC molecules.
Ubiquitination by MuRF1 has recently been shown to regulate the
disassembly and degradation of the myofibrillar proteins MyBP-C,
MLC1, and MLC2; however, MyHC is not ubiquitinated by
MuRF1 in vitro when associated in the actomyosin complex or in
the intact myofibrils [10]. Interestingly, ubiquitin-dependent
degradation has also been indirectly implicated in the regulation
of myosin folding and assembly [11].
Ozz, also known as Neurl2 (Neuralized-like protein 2), is the
substrate-binding component of a RING (Really Interesting New
Gene)-type ubiquitin ligase complex, which comprises Elongin B/
C (Elo B/C), Rbx1 and Cullin 5 (Cul5) [12]. The protein primary
structure contains two Neuralized Homologous Repeats (NHR1
and NHR2) that serve as protein-protein interaction domains and
a SOCS (Suppressor of Cytokine Signaling) box at the C-terminus
for recognition by the Elo B/C subcomplex. Ozz expression is
muscle-specific and upregulated during muscle fiber differentia-
tion, but we show here that it is downregulated in muscle atrophy.
To form an active E3 ligase, Ozz must assemble with the other
components of the complex, a process that adds an extra tier to
regulation of substrate recognition and ubiquitination by this ligase
[12]. This is in contrast to the MuRF family of ubiquitin ligases,
which are monomeric and can initiate ubiquitination immediately
upon binding their substrates [8,9,13].
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substrate for Ozz-E3 and that ozz
2/2 mice develop overt
sarcomeric defects, which we have attributed in part to the
impaired turnover of b-catenin at the membrane of differentiating
myofibers [12].
We report here that the sarcomeric embryonic myosin heavy
chain (MyHCemb/Myh3) is a novel substrate of Ozz, which
specifically recognizes the rod domain or tail region of this protein.
MyHCemb expression is associated with initiation of sarcomere
formation [14], leading to the idea that it is optimized for self-
assembly into new thick filaments followed by a sequence of
subunit changes to give rise to adult myofilaments [15].
Embryonic muscles form in two stages: a small number of primary
myotubes form a scaffold to direct the later formation of secondary
myotubes, which give rise to the majority of adult muscle fibers
[16–18]. MyHCemb, together with MyHCslow, is expressed during
primary myotube formation, and again together with MyHCneo,
during secondary myotube formation [19,20]. It also is the first
myosin isoform to be expressed when new myotubes form in
regenerating adult muscle [21]; in intact adult muscles during
hypertrophy induced by passive stretch [22]; or during recovery
from immobilization-induced atrophy [23]. Shortly after birth it is
rapidly replaced by adult myosin isoforms [20,24].
Here we present evidence that the Ozz-E3 ligase, by binding to
the rod domain of a fully assembled MyHCemb, marks it for
ubiquitination and degradation, probably facilitating the subse-
quent assembly of new isoforms. These observations lead to the
idea that in muscle tissue the ubiquitin-proteasome system, in
addition to its involvement in atrophy, removal of misfolded/
damaged proteins, and proper folding and assembly of structural
proteins, may also facilitate exchange of isoforms within large
polymeric assemblies to regulate tissue development, remodeling
and regeneration.
Results
Ozz is Downregulated in Muscle Atrophy
Up-regulation of ubiquitin ligases and protein ubiquitination are
common correlates of muscle atrophy. We have shown earlier that
the expression of ozz mRNA and Ozz protein increases during
muscle development from embryonic day E12.5 onward [12]
(Fig. 1A). We now wished to test if there was a similar response
with muscle atrophy. Ozz levels progressively fell following
denervation (Fig. 1B), suggesting the involvement of Ozz in
muscle growth rather than atrophy. The latter conclusion was
further supported by the pattern of Ozz expression upon injury of
adult muscles with local injection of cardiotoxin. This procedure
provokes initial profound muscle degeneration, followed by
regeneration [21,25]. Ozz expression was downregulated during
the phase of degeneration, but was upregulated during the
regeneration phase (Fig. 1C), confirming that Ozz expression is
associated with muscle development and growth.
Ozz Targets Embryonic Myosin Heavy Chain
In a yeast 2-hybrid screen of an E14.5 mouse cDNA library we
identified MyHCemb as a novel interaction partner of Ozz. Either
full-length Ozz or the N-terminal half of the protein (residues 1–
229), including the entire NHR1 domain (residues 14–104) and
most of the NHR2 domain (residues 208–242) were used as baits.
Both screens yielded 3 clones with 93% homology to MyHCemb
spanning residues 1042–1941 of the tail domain (Fig. 1D). To
confirm Ozz’ interaction with the tail of MyHCemb and to identify
the minimal regions of the tail needed for this interaction, we
performed a series of 2-hybrid experiments using as preys either
the full length tail domain (residues 1040–1941), the full length
head/neck domain (residues 1–1040), or several deletion mutants
of the tail region (Fig. 1E and Fig. S1A). These mutant peptides
either included or excluded a 29 amino acids (1873–1901 aa)
assembly competence domain (ACD) near the C-terminus of the
myosin tail, which is responsible for proper myosin assembly into
thick filaments [26]. We found that Ozz interacted strongly with
the full-length tail, but not with the head/neck domain. Two
deletion fragments of the myosin tail encompassing either the N-
terminal amino acids 1041–1535, or the C-terminal amino acids
1536 to 1941 interacted differently with the full length Ozz: the
former bound weakly, while the latter maintained a strong
interaction (Fig. 1E and Fig. S1A). By further deleting the latter
fragment at either its C-terminus (1738–1941 aa) or N-terminus
(1536–1871 aa) we completely abolished Ozz binding. Similarly,
two truncated fragments spanning amino acids 1872–1941,
encompassing the ACD domain, also showed no interaction with
Ozz. These results identified at least two regions of the MyHCemb
tail crucial for Ozz binding, which likely depends on the 3D
folding of the MyHCemb tail.
To verify whether the Ozz-MyHCemb interaction occurred in
vivo, crude lysates of proliferating (day 0), differentiating (day 2)
and terminally differentiated (day 4) primary myoblast cultures
prepared from newborn wild-type mice were immunoprecipitated
with anti-MyHCemb antibody or an isotype matching control IgG,
and probed on immunoblots with anti-Ozz antibody. The results
showed that Ozz was effectively co-immunoprecipitated with
MyHCemb, indicating that the two endogenous proteins were
firmly linked (Fig. 2A).
We next tested if Ozz could exert its ubiquitin ligase activity
towards MyHCemb. For this purpose we performed in vitro
ubiquitination assays using a purified, reconstituted Ozz-E3
complex [12] and a GST-tagged MyHCemb fragment spanning
the tail portion of the protein (residues 1041–1942). The
ubiquitinated products were then immunoprecipitated with anti-
MyHCemb and the immunoblots probed with anti-ubiquitin
antibody or anti-GST antibody, used as control (Fig. 2B).
Recombinant MyHCemb tail and its proteolytic fragments of
smaller molecular weight were ubiquitinated only in the presence
of the Ozz-E3 complex (Fig. 2B, compare lanes 4 and 5).
Furthermore, if the assay was performed using the ubiquitin
mutant K48R to avoid the formation of a conjugated ubiquitin
chain at this residue, ubiquitination was reduced to background
levels (Fig. 2B, lane 6), demonstrating that Ozz-E3 polyubiquiti-
nated the MyHCemb tail. Five other GST fusion proteins, used as
internal controls, were not ubiquitinated in this assay (data not
shown), confirming the specificity of Ozz-E3 activity towards its
substrate.
Ozz Segregates with Fully Assembled Sarcomeric Myosin
during Myofibrillogenesis
In a chaperone-mediated process [27–30] newly synthesized
myosin isoforms are serially polymerized as monomers; dimers
plus 4 myosin light chains (MLC) to form hexamers; and
assembled thick filaments. To determine which pool of myosin is
targeted by Ozz in vivo we first tested the chromatographic profiles
of Ozz and MyHCemb after gel filtration of muscle extracts from
embryos of different stages (E14.5–E18.5). Myosin preparations
conventionally employ high ionic strength extraction buffers to
solubilize fibrillar myosin. Here we used differential centrifugation
of muscle lysates of wild-type embryos in a buffer close to
physiological ionic strength to obtain a supernatant containing
mostly soluble myosin (S) and an insoluble high-speed pellet
including sarcofilamentous myosin (P). Examination of the P
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firmed the presence of fragments of sarcomeres staining positively
for MyHCemb and a-actinin (data not shown), which validated our
extraction procedure. We then separated the P and S myosin
preparations on gel filtration columns and assessed the levels and
distribution of MyHCemb and Ozz on immunoblots of the eluted
fractions probed with anti MyHCemb, anti-Ozz and anti-MLC
antibodies. The profiles shown in Fig. 3 (upper panels) were
generated by densitometric analyses of band intensities.
Throughout myofibrillogenesis (E14.5-E18.5) full-length myosin
eluted from the column mainly in two groups of fractions in the
size ranges <1500–900 kDa and <800–500 kDa. These fractions
from both sarcomeric (Fig. 3) and soluble myosin preparations
(data not shown) contained MyHCemb and MLC, indicating the
presence of multimeric myosin (<1500–900), myosin hexamers (2
heavy chains and 4 light chains, MW 520 kDa), as well as lower
mwfragments.Athirdgroupoffractions,correspondingtosizes,<
200 kDa, contained reproducible anti-MyHCemb +ve bands of
<50 kDa, 30 kDa and 25 kDa, evidently myosin peptides (Fig. 3).
Their size distribution indicated that some passed through the
column as dimers. The separation pattern of the different
MyHCemb bands varied only slightly among embryos of different
ages.
In the same high molecular weight column fractions of
sarcomeric preparations (P), a portion of Ozz consistently co-
eluted with filamentous myosin, suggesting that Ozz is already
bound to sarcomeric myosin during the early stages of myofi-
brillogenesis (E14.5, Fig. 3). In contrast, Ozz was totally absent
from all fractions in the size range <1500–550 kDa from the S
preparations (data not shown). Free Ozz eluted from the column
in size fragments near its monomeric molecular weight of <31
kDa and was detected at comparable levels in both the P and S
preparations.
The finding that Ozz co-elutes with the high molecular weight
pool of MyHCemb on size exclusion columns was further
supported by immunofluorescence labeling of differentiated
primary myotubes (day 4), treated and not treated with the MG-
132 proteasome inhibitor, using anti-Ozz and anti-MyHCemb
antibodies (Fig. 4). Confocal microscopy and computational
analyses of the two fluorescent signals indicated that a selected
pool of sarcomeric MyHCemb co-localized with Ozz in the
untreated myotubes (Fig. 4A and C). Given that the co-localization
of the two proteins increased substantially in fibers treated with the
proteasome inhibitor, as determined by the co-localization
coefficient (Fig. 4B and D), we can infer that Ozz regulates the
proteasomal degradation of a selected pool of sarcomeric
MyHCemb during myofiber differentiation.
Ozz Interacts and Ubiquitinates Fully Assembled
Sarcomeric Myosin
Having established that a portion of the Ozz protein segregates
with assembled MyHCemb, we wanted to ascertain whether Ozz
was detectable in a classical preparation of muscle thin-thick
filaments from E16.5 embryos [31,32]. We chose E16.5 embryos
because this embryonal stage coincides with the onset of secondary
myogenesis. Western blot analysis of these preparations demon-
strated the co-purification of Ozz and its direct interacting partner
Elo C with the thin-thick filaments, indicating an association of the
entire Ozz-E3 complex with fully assembled myosin (Fig. 5A). To
further validate these results, we checked whether all components
of the Ozz-E3 complex were bound to assembled myosin in the
insoluble preparations (P) from muscles of E16.5 embryos. Direct
interaction of Ozz with myofilamentous MyHCemb was proven by
co-immunoprecipitation of Ozz with anti-MyHCemb antibody
only from the insoluble preparations (P), but not from the soluble
preparations (S), albeit the amount of Ozz was greater in the latter
(Fig. 5B, panels 2 and 6). Together these data show that Ozz is
bound in a stable form to assembled sarcomeric myosin since the
early stages of myofibrillogenesis, but at an untraceable level to
soluble myosin.
Fractions from both S and P preparations were also probed on
immunoblots with antibodies against each component of the Ozz-
E3 complex (Elo B/C, Cul5, and Rbx1). Notably, all 4 proteins
were detected together with Ozz not only in the soluble pool (S) of
extracted muscle proteins but also in the insoluble sarcomeric
preparations from wild-type embryos (Fig. 5B, panels 7–10).
Furthermore and in agreement with the observed presence of both
Ozz and Elo C in purified thin-thick filaments (Fig. 5A), we found
a portion of Ozz bound to Elo C within the myofibrils (P fraction)
but not in the soluble (S) fraction (Fig. 5B, panel 4). To ascertain
whether the other components of the Ozz-E3 complex associated
with the Ozzylated sarcomeric MyHCemb, extracted muscle
proteins were immunoprecipitated with anti-Elo C from the S
and P fractions and probed on immunoblots with both anti-
MyHCemb and antibodies against the remaining E3 components.
We found that MyHCemb was effectively co-immunoprecipitated
with anti-Elo C (Fig. 5B, panel 5). However, under these stringent
experimental conditions (high salt concentration), while we were
able to demonstrate Ozz binding with its direct interacting
partners, MyHCemb and Elo C, we could not co-immunoprecip-
itate the remaining components of the Ozz-E3 complex (not
shown). Nonetheless, the presence in the sarcomeric, insoluble
fractions of all Ozz partners and the demonstrated interaction of
Ozz, Elo C and MyHCemb strongly support the notion that the
Ozz-E3 complex is assembled within the myofibrils.
Finally, to test whether MyHCemb was efficiently ubiquitinated
by Ozz-E3 when associated with the myofibril, we used
sarcofilamentous myosin, purified from wild-type newborn muscle
[33,34], as substrate in an in vitro ubiquitination assay. We found
that Ozz-E3 efficiently ubiquitinated the endogenous, assembled
MyHCemb (Fig. 5C). The specificity of the reaction was confirmed
by the lack of ubiquitinated products in the absence of either the
substrate (lane 2) or the Ozz-E3 complex (lane 3).
MyHCemb Expression Persists in Ozz
2/2 Muscle
Mouse myoblasts in primary culture multiply and then quickly
fuse into multinucleated myotubes expressing MyHCemb and other
MyHC isoforms. Immunoblots of lysates of primary myoblasts
induced to differentiate in vitro confirmed that Ozz expression was
Figure 1. Ozz Expression Is Upregulated During Development and Regeneration, but not Atrophy. (A) Ozz is present during the initial
phase of myogenesis (E12.5) and expression progressively increases during embryonic muscle development. (B) Expression of Ozz in the
gastrocnemius muscle progressively decreases during denervation-induced muscle atrophy. (C) Ozz expression following cardiotoxin injection falls
during the degeneration phase (2–4d post-injection) and then increases during the regeneration phase (5–10d post-injection) before returning to
control levels. (D) Schematic diagram of a myosin molecule, depicting the position of the 3 cDNA clones within the tail portion of MyHCemb isolated
by a yeast 2-hybrid screen. (E) To map the Ozz binding region(s) on MyHCemb, various MyHCemb constructs were screened against full length Ozz in a
yeast 2-hybrid system. Two reporter genes (HIS3 and LacZ) were employed to assess protein-protein interaction. Amino acid residues are indicated.
HMM, heavy meromyosin; LMM, light meromyosin; ACD, adhesion competence domain.
doi:10.1371/journal.pone.0009866.g001
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of immuno-positive myosin bands to the Hsp 70 loading control in
three independent experiments showed that in wild-type myotubes
MyHCemb levels peaked at day 3 and then fell as expression of
other isoforms increased (Fig. 6A and B); this pattern of expression
has been described in both mouse and human muscle cultures
[14,35]. In ozz
2/2 myotubes, by contrast, at day 4 and day 5 of
differentiation MyHCemb levels remained significantly higher than
in control myotubes (Fig. 6A and B). This observation was further
confirmed by measuring the mean fluorescence intensity of
individual wild-type and ozz
2/2 primary myotubes (day 4) (Fig.
S2A and B). A significant increase in the fluorescence intensity of
MyHCemb was detected in ozz
2/2 myotubes compared to wild-
type myotubes (Fig. S2B), suggesting improper regulation of this
myosin isoform during myotube formation.
Shortly after birth, MyHCemb expression normally falls
rapidly, becoming undetectable within 2–3 weeks postnatal
[ 2 0 ] .T ot e s ti fe x p r e s s i o no fM y H C emb protein was also
disturbed in the ozz
2/2 mice, we compared the amount of
MyHCemb in ozz
2/2,o z z
+/– and ozz
+/+ muscles isolated from the
limbs of 7.5-day-old mouse pups. Immunoblots and quantitative
analyses of these preparations demonstrated that ozz
2/2 and
heterozygous pups had a significantly higher proportion of
MyHCemb in the insoluble myosin fraction than their corre-
sponding wild-type littermates (Fig. 6C and D). By contrast, wild-
type soluble myosin had a relatively greater proportion of
MyHCemb than the corresponding ozz heterozygous and
knockout samples (Fig. 6C, middle panel). A prominent
proteolytic fragment of about 50 kDa was similar in all samples
(Fig. 6C, middle panel, arrowhead). The levels of MLC in both
insoluble and soluble fractions paralleled those of MyHCemb
(Fig. 6C, MLC). Total MyHC (antibody MF20) was used as
additional control (Fig. 6C). Together these observations denote
a phenotype of slowed release of MyHCemb from sarcomeric
myofilaments in postnatal ozz
2/2 muscle tissue. Heterozygotes,
which have around half the normal level of expression of Ozz,
also had increased levels of insoluble myosin, suggesting that Ozz
may be regulatory as well as necessary for normal embryonic
myosin isoform disassembly and replacement with the postnatal
isoform. One possibility is that an Ozz molecule must attach to
each monomer in a MyHCemb dimer to efficiently promote its
ubiquitination and removal, making the process sensitive to
absolute levels of Ozz expression.
These biochemical data were confirmed by immunofluores-
cence and confocal microscopy analyses of cross sections of the
hind limbs from P7.5 wild-type and null pups. In ozz
+/+ muscles
we found that MyHCemb was in course of being removed and
replaced by other MyHC isoforms. In fact, many fibers sectioned
near the mid-belly region of individual wild-type muscles showed
little or no expression of MyHCemb, which was instead more easily
detected in sections near the muscle tendon region of the muscle,
indicating a gradient in isoform displacement from the middle
towards the ends of the muscle fibers. By contrast, matched
sections of ozz
2/2 limbs displayed a higher number of MyHCemb
expressing fibers throughout the length of the muscles, but most
prominently near the muscle tendon region. The sections were cut
at the level of the distal third of the gastrocnemius and tibialis anterior
muscles to include the intra-muscular tendons, and labeled with
anti-MyHCemb and phalloidin. Fig. 7A shows a high magnification
representative of these sections at the level of the gastrocnemius.
Contrary to the wild-type limb muscles (Fig. 7A, lower panels),
every fiber close to the tendon in the ozz
2/2 muscles expressed
high levels of MyHCemb (Fig. 7A, upper panels) as did the majority
of peripheral fibers of the same muscle. A quantification of the
Figure 2. Ozz Binds MyHCemb to Promote its Ubiquitination. (A)
Lysates of undifferentiated cultured myoblasts (day 0) and differenti-
ating or differentiated myotubes (days 2–4) were subjected to
immunoprecipitation using anti-MyHCemb, anti-Ozz antibodies, or
isotype matching IgG as control. Immunoblotting of the co-precipitated
proteins as well as the total lysates with anti-MyHCemb and anti-Ozz
antibodies demonstrated that Ozz and MyHCemb are bound in a stable
complex. (B) In vitro ubiquitination of recombinant MyHCemb mediated
by Ozz-E3 ligase. A GST-tagged MyHCemb fragment of <130 kDa (1041–
1942 aa), which included the myosin rod region, was incubated with
Ozz-E3 ligase and either native ubiquitin or a mutant Ub K48R. In the
presence of Ozz-E3 ligase and native ubiquitin the MyHCemb fragment
was efficiently ubiquitinated. (Lane 1) Coomassie-stained gel of the
GST-MyHCemb fragment used as substrate for the reaction. (Lane 2)
Immunoprecipitation of GST-MyHCemb fragment with anti-MyHCemb
antibody, followed by immunoblotting with anti-MyHCemb. (Lane 3–6)
Immunoprecipitation of the in vitro ubiquitinated GST-MyHCemb
fragment with anti-MyHCemb antibody, followed by immunoblotting
with anti-GST (3) or anti-Ubiquitin (4–6). In vitro ubiquitination reactions
were as follows: (lane 4) Ozz-E3 + ubiquitin - MyHCemb; (lane 3 and 5)
Ozz-E3 + ubiquitin + MyHCemb; (lane 6) Ozz-E3 + ubiquitin mutant K48R +
MyHCemb.
doi:10.1371/journal.pone.0009866.g002
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length of the limbs is shown in Fig. 7B.
Discussion
We have previously described the identification of Ozz as the
substrate-recognition component of a striated muscle-specific
RING-type E3 ubiquitin ligase complex, involved in myofiber
differentiation [12]. Here, we present evidence that Ozz plays a
critical role in muscle development and regeneration, but not in
muscle atrophy. In addition, we found that during muscle
differentiation Ozz recognizes the developmental isoform MyH-
Cemb as one of its substrates, marks it for ubiquitination, and is
both necessary and sufficient for its ubiquitination in an in vitro
assay. Ozz binding to MyHCemb differs from that of other E3
ligases in that it targets the tail portion of assembled sarcomeric
myosin rather than the head portion of soluble myosin, and we
suggest that these properties are fundamental to its role in muscle
development as opposed to muscle atrophy.
MyHCemb is the majority myosin isoform in embryonic and
neonatal muscle fibers and its expression declines after birth to
become undetectable around 3 weeks postnatal [20]. This
postnatal decline is a robust process, not affected in null mutants
of other myosin isoforms [20] or in animals where development of
adult isoforms is retarded by undernutrition [36]. However, we
found that the decline is slowed in a model system of dif-
ferentiating ozz
2/2 primary myoblasts and in postnatal ozz
2/2
muscles.
During myofibrillogenesis, the developmental exchange of
MyHC isoforms requires a myosin molecule to be released from
its complex insertion into a sarcomeric thick filament, in order to
be replaced by a subsequently expressed isoform. Davis, in a
model of this process [2], concluded that core myosin molecules
within a myofilament are essentially inaccessible to exchange by
mass action and that a ‘‘facilitated exchange’’ process must exist in
order to account for the rapid and complete change of isoforms
observed in vivo. Without an additional regulatory process,
exchange at equilibrium would be limited to the exchange of
subunits away from the center of the filament.
We found that Ozz is associated with sarcomeric but not soluble
MyHCemb from the earliest stages of muscle formation. The fact
that Ozz and its direct partner Elo C could be co-immunopre-
cipitated from sarcomeric but not soluble myosin extracts of E16.5
embryonic muscle indicates that at this age a proportion of Ozz
molecules bound to MyHCemb is assembled into the E3 ligase
complex. We also demonstrated that formation of such a complex
is sufficient for in vitro ubiquitination of sarcofilamentous
MyHCemb. From these findings, we can infer that the orderly
removal of assembled MyHCemb is achieved by tagging it with the
Ozz-E3 ubiquitin ligase (Fig. 8). This refined mechanism,
exchanging single molecules within a macromolecular assembly,
would enable isoform exchange without any necessity for
demolition and reconstruction within the cell, and is expected to
represent a principle, which may be exploited by other subcellular
systems. Moreover, our findings complement recent work on
myosin assembly, which requires the coordinated action of
Figure 3. Ozz Segregates with Myofilamentous MyHCemb from
the Earliest Stages of Myofibrillogenesis. Sarcomeric (P) fractions
from E14.5 (top), E-16.5 (middle), and E18.5 (bottom) embryonic
muscles were separated according to their molecular size (horizontal
axis) by gel filtration chromatography. Aliquots of each eluted fraction
were separated by SDS-PAGE and then immunoblotted with anti-
MyHCemb (green), anti-Ozz (red), and anti-MLC (blue). The average
intensities from three experiments were measured and plotted, as
indicated. The densitometric analysis of the protein profile shows that
the high molecular weight fractions (<1500 kDa - <900 kDa) of
sarcomeric (P) preparations contained polymeric myofilamentous
MyHCemb, as confirmed by the presence of MLC. Ozz co-eluted with
the high molecular weight myofilamentous MyHCemb only in the
sarcomeric (P) fractions, but was conspicuously absent from the
cytoplasmic fractions (data not shown). Ozz and MLC also eluted in
size fractions corresponding to their monomeric molecular weights, in
both sarcomeric and cytoplasmic subcellular fractions (data not shown).
doi:10.1371/journal.pone.0009866.g003
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myosin ready for insertion into sarcomeric thick filaments.
Myosin assembly into thick filaments depends on a 29 amino
acid assembly competence domain (ACD) near the C-terminal end
of the myosin rod domain [26]. We found that Ozz recognizes the
rod portion of MyHCemb, which forms the core of sarcomeric
thick filaments where it is not easily accessed for binding or
exchange by soluble cytoplasmic molecules. This is in contrast to
the other known myosin E3 ligases, which target the head region
of myosin [9], the portion of myosin exposed for interaction with
actin and ATP. Furthermore, they appear able to access only
sarcoplasmic, not sarcomeric myosin [9,38], and their E3 ligase
activity does not require further activation once they have
recognized their substrate.
We hypothesize that during muscle fiber differentiation
sarcomeric MyHCemb becomes ubiquitinated by the Ozz-E3,
and dissociates from the rest of the sarcomere. We showed that
Ozz and Elo C are present together with sarcomeric myosin from
the earliest stages of myofibrillogenesis, but we saw no obvious
increase in Ozz/MyHCemb ratio in association with the onset of
peak periods of MyHCemb degradation during embryogenesis (e.g.
Fig. 3C vs. Fig. 3A, 3B). On the basis of these results, we conclude
that Ozz-E3 ligase promotes the ubiquitination and the degrada-
tion of sarcomeric MyHCemb (Fig. 8).
However, we cannot exclude that this process may occur in two
phases. This alternative model implies that, in contrast with the
action of one-chain ligases, Ozz does not immediately initiate
ubiquitination and proteolytic degradation but may have a
chaperone-like function in a preassembled form and only
subsequently may gather the rest of the complex and become an
active ligase. This two-step mode of action of the Ozz-E3 may
explain the timely and regulated replacement/exchange of
myofilamentous myosin during muscle differentiation and regen-
eration. This model of regulated assembly and disassembly of
MyHC could be envisaged also for the adult muscle, where Ozz is
expressed at basal levels [12]. In the adult muscle the Ozz-E3
activity would ensure the maintenance of myofiber integrity and
the regulated exchange of isoforms under stress fiber conditions.
Modulation of cell structure by disaggregation and reassembly
of cytoskeletal subunits is common to all cells, as is ubiquitination
of many of the signaling proteins that control this process. The
ubiquitin system also regulates signaling proteins controlling cell
metabolism, cell cycle, and ion channel turnover, and is involved
in chaperone-mediated myosin assembly [27–30]. It has a
Figure 4. Co-localization of Ozz with Sarcomeric MyHCemb during Myofiber Differentiation. (A) and (B) Confocal microscopy images of
differentiating myotubes (day 4) untreated (A) and treated (B) with MG-132. Cells treated with the proteasome inhibitor showed a clear increase of co-
localization of MyHCemb and Ozz compared to untreated myotubes. (C) and (D) Computational analyses of confocal images of differentiated myotubes
untreated (C) and treated (D) with MG132 confirmed the visualization of the co-localized fluorochromes. Pearson’s correlation coefficient (Rr), Manders
overlap (R), and Manders overlap coefficients k1 and k2 were employed to evaluate the extent of colocalization of the two fluorescent dyes.
doi:10.1371/journal.pone.0009866.g004
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promoting their degradation, and has a particular association with
muscle atrophy. However, Ozz is upregulated during develop-
ment, growth and regeneration, and downregulated in atrophy,
and represents to our knowledge the first E3 ligase to be described
as having a role in targeting myosin in its fully assembled
sarcomeric structure during muscle remodeling. The Ozz model
may be a paradigm for other developmental systems requiring
protein isoform exchange within complex cytoskeletal structures.
Materials and Methods
Yeast Two-Hybrid Screening
Screening of an E14.5 mouse cDNA library (gift of P.
McKinnon) for putative Ozz-binding partners was performed as
previously described [12]. Three cDNA clones encoding the tail
portion of MyHCemb were isolated. To confirm the absence
of interaction with the head and neck portion of MyHCemb the
corresponding prey construct (1–1047 aa) cDNA was ampli-
fied using a 10 ml reverse transcription reaction with primers
59-GAGGGTGGGTCGACCATGAGTAGCGACACCGAGA-
TGG-39 and 59-TACTTAGCGGCCGCTCATTGTTCGAGG-
GAGCTCTCCAG-39. The RT-PCR product was cut with Sal1
and Not1 and inserted into the prey vector pEXP-AD502 in frame
with the GAL4 activation domain. The deletion mutants of the
MyHCemb tail region were amplified using appropriate primers
(see below). These PCR fragments were digested with Sal1 and
Not1 and subcloned into the prey vector pEXP-AD502 in frame
with the GAL4 activation domain. For yeast two hybrid assays, the
bait and prey constructs were co-transformed into yeast strain
Mav203. Two reporter genes (HIS3 and LacZ) were employed to
study the protein (Invitrogen).
Figure 5. Ozz Interacts with Myofilamentous MyHCemb. (A) Ozz was recovered in a classical preparation of thin-thick filaments from E16.5
embryonic muscle, demonstrating that it is stably bound to sarcomeric myosin. Also, the presence of Elo C in this preparation indicates that the Ozz-Elo
C sub-complex is associated with the myofilaments. (B) Cytoplasmic (S) and sarcomeric (P) fractions from wild-type E16.5 embryonic muscles were
analyzed on Western blots for the presence of Ozz and its binding partners Elo B, Elo C, Cul5, Rbx1. The same preparations were also subjected to
immunoprecipitation with anti-MyHCemb or anti-Elo C, and the immunoprecipitates blotted and probed with anti-MyHCemb, anti-Ozz or anti-MLC. Ozz
co-immunoprecipitated with MyHCemb and Elo C only from the sarcomeric fractions, not the cytoplasmic fractions. (C) In vitro ubiquitination of native
sarcofilamentous myosin purified from wild-type newborn muscle (P1). (Lane 1) Ozz-E3 efficiently ubiquitinated sarcomeric MyHCemb. The specificity of
the reaction was confirmed by omitting either the substrate (lane 2) or the Ozz-E3 complex (lane 3) from the ubiquitination assay, which significantly
reduced the Ub-MyHCemb products. Note the similarity with (B) panel 1, identifying the high molecular weight smear as ubiquitinated MyHCemb.
doi:10.1371/journal.pone.0009866.g005
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MyHCemb (1042–1535 aa): Forward GAGGGTGGGTCGAC-
CAAGAAGCTGCGTGTGGA
CCTA; Reverse TACTTAGCGGCCGCTCACTCCATCT-
GTTTTCTGGATTT.
MyHCemb (1536–1941 aa): Forward AGGCTTGTCGAC-
CCTGGAGAAGGCTGACATCC
AGA; Reverse CGCGTGCGGCCGCTCACTCCTCGCTT-
TCATGGACCAC.
MyHCemb (1738–1941 aa): Forward AGGCTTGTCGACCC-
TCCAGAGTGAGGTGGAGG
AT; Reverse CGCGTGCGGCCGCTCACTCCTCGCTTT-
CATGGACCAC.
MyHCemb (1536–1871 aa): Forward AGGCTTGTCGACCC-
TGGAGAAGGCTGACATCCA
GA; Reverse CGCGTGCGGCCGCTCATTTATCCACCA-
GATCCTGCAA.
MyHCemb (1872–1941 aa): Forward GGCTTGTCGACCCT-
CCAAGTGAAAGTCAAGTCC;
Reverse CGCGTGCGGCCGCTCACTCCTCGCTTTCAT-
GGACCAC.
MyHCemb (1901–1941 aa): Forward GCTTGTCGACCCAG-
CATGAGCTAGAGGAGGCC
Reverse CGCGTGCGGCCGCTCACTCCTCGCTTTCAT-
GGACCAC.
Surgical Procedures
All animal experiments were performed according to animal
protocols approved by our Institutional Animal Care and Use
Committee and National Institutes of Health guidelines. C57Bl/6
wild-type and ozz-null mice [12] were anaesthetized with
isofluorane, and following surgery received ibuprofen, 7.5 mg/kg
daily, for pain relief. Muscles of the lower hind limbs were
denervated by sectioning the sciatic nerve in the lower thigh, just
above the common peroneal–tibial nerve junction. Alternatively,
they were tenotomised by sectioning the Achille’s tendon. Muscle
degeneration–regeneration was induced by injecting 10 mM
cardiotoxin into the gastrocnemius (100 ml) or tibialis anterior (30 ml)
muscles of 1–3 month-old mice. All experimental muscles were in
the right limbs, with the left used as controls. Mice were sacrificed
by CO2 inhalation before dissection.
Isolation of Embryonic Muscles
Dated pregnant mice were sacrificed by CO2 inhalation, and
the uterus quickly removed and placed on ice. Individual embryos
were pinned on a Sylgard dish and dissected under ice-cold saline
solution. The viscera, skin and spinal cord were removed and the
embryo decapitated, leaving muscles of all four limbs, ribcage and
back, with their associated cartilage. Tissues were snap frozen in
liquid nitrogen.
Cell Cultures
Myoblast cultures were established as described previously
[12,39,40].
Antibodies and Reagents
Rabbit anti-Ozz antibody was prepared as described [12]. The
antibody was diluted 1:500 for Western blotting and 1:10 for
immunofluorescence. Mouse monoclonal antibodies anti-MyH-
Cemb (F1.652) 1:400, anti-MLC (T14) 1:500, and anti-pan myosin
(MF20) 1:500 were purchased from the Developmental Studies
Hybridoma Bank. Anti-MyHCemb (2B6) 1:500, was a gift from Dr.
N. Rubinstein. Other commercial antibodies included mouse anti-
GST 1:500 (UPSTATE), mouse anti-ubiquitin 1:500 (Zymed),
anti-Elo C 1:300 (BD Biosciences), anti-GAPDH 1:5000 (Milli-
pore), rabbit anti-Elo B 1:300 (Santa Cruz), anti-Rbx-1 1:500
(Thermo Scientific), anti-Cul5 1:200 (Santa Cruz), anti-pan actin
1:5000 (Cell Signaling), normal mouse IgG (Santa Cruz), anti-Hsp
70 1:4000 (Novus Biologicals), Cy3-conjugated anti mouse IgG
and Cy3-conjugated anti-rabbit 1:500 (Jackson ImmunoResearch),
Alexa Fluor 488-conjugated anti-mouse 1:500 (Invitrogen), FITC-
Phalloidin 1:500 (SIGMA-ALDRICH) and MG-132 (Enzo Life
Sciences).
Co-immunoprecipitation
Ozz-MyHCemb complexes were detected in crude lysates of
myoblast by immunoprecipitation with anti-MyHCemb antibody,
followed by Western blotting of the immunoprecipitates with the
anti-Ozz antibody. Cultured myoblasts were lysed (lysis buffer:
50 mM HEPES (pH 7.5), 150 mM NaCl, 1% Igepal CA-630,
0.5% deoxycholate, 0.1% SDS, 5 mM EDTA, 1 mM EGTA,
1 mM DTT, 1 mM PMSF, protease inhibitors, phosphatase
inhibitor), incubated at 4uC for 30 min, and cellular debris were
pelleted by 20 min centrifugation at 12000 x g. The lysate was pre-
cleared by 1 hr incubation at room temperature with 30 mlo f
Gamma Bind Plus Sepharose beads (Amersham Biosciences) and
then spun at 15006g. Anti-MyHCemb (2B6) or anti-Ozz antibody
was added to the supernatant and incubated for 1 hr at room
temperature, followed by immunoprecipitation with Gamma Bind
Plus Sepharose beads and overnight incubation at 4uC. The beads
were washed 3x with lysis buffer, and 1x with lysis buffer without
detergents, and the bound proteins detached and run on SDS-
polyacrylamide gels under denaturing conditions.
Fractionation of Muscle Tissues and
Co-immunoprecipitation
Muscles from E14.5, E16.5, and E18.5 embryos were
homogenized for 60s in a Dounce homogenizer in 4 volumes of
lysis buffer [28] (Tris-HCl, 20 mM, pH 8.0; NaCl, 200 mM;
MgCl2, 5 mM; DTT, 5 mM) and centrifuged at 160006g for
5 min. The supernatant was then spun at 100,0006g for 2.5 hr at
4uC. The resulting supernatant was kept as the S fraction
Figure 6. MyHCemb Expression is Abnormally Prolonged in Ozz
2/2Mutants. (A) MyHCemb expression is prolonged during in vitro
differentiation of ozz
2/2 primary myoblasts. Western blots showing the time course of MyHCemb and Ozz expression in undifferentiated myoblasts
(day 0) and differentiating or differentiated multinucleated myotubes (day 1–5) from null mutants and wild-type controls. (B) Quantification of
MyHCemb expression in the soluble fractions shown in (A), normalized against Hsp 70 levels. Data are expressed as mean 6 SD of three independent
experiments. Groups were compared by the Student t-test for two samples assuming equal variance. Mean differences were considered statistically
significant when P values were less than 0.05 (*). (C) Western blot analyses of the sarcofilamentous, insoluble fractions of muscle isolated from ozz
+/+,
ozz
+/–, and ozz
2/2 P7.5 pups showed that the expression of MyHCemb is greater in the null and heterozygous samples than in the wild-type samples.
In contrast, in the cytoplasmic, soluble fraction from the same preparations the expression of MyHCemb is greater in the wild-type samples. Ozz
expression is approximately halved in heterozygotes, while MLC expression remains normal. GAPDH is shown as loading control. (D) Quantification of
MyHCemb expression in the insoluble fractions shown in (C), standardized against GAPDH expression. Data are expressed as mean 6 SD of three
independent experiments. Groups were compared by the Student t-test for two samples assuming equal variance. Mean differences were considered
statistically significant when P values were less than 0.05 (*).
doi:10.1371/journal.pone.0009866.g006
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fraction was resuspended in 600 ml of lysis buffer.
S and P fractions prepared from E16.5 embryos were
immunoprecipitated with anti-Elo C or anti-MyHCemb using
Protein G Dynabeads (Invitrogen), as described above.
Gel filtration Columns of S and P Fractions
S and P fractions were separated on a Superose 6 gel filtration
column (GE Healthcare). Aliquots from the gel filtration column
were then denatured and run on SDS-polyacrylamide gels,
followed by Western blotting with the appropriate antibodies.
For calculation of the molecular weight the column was calibrated
with the following proteins: thyroglobulin, 669 kDa; apoferritin,
443 kDa; b-amylase, 200 kDa; carbonic anhydrase, 29 kDa
(SIGMA). At least 54 aliquots were analyzed, giving a size
resolution from <2000 kDa to ,10 kDa.
In vitro Ubiquitination of GST-MyHCemb Fragment
Four mg of a bacterially expressed GST-MyHCemb frag-
ment (1041–1941 aa) was incubated with 150 ng of puri-
fied recombinant E1 (Calbiochem), 200 ng UbcH5b (a gift of
D r .B .S c h u l m a n ) ,1 . 0mg Ozz-E3 ubiquitin ligase and 7.5 mg
of ubiquitin (Calbiochem) or K48R ubiquitin (Calbiochem) in
a final volume of 30 ml of ubiquitination buffer (0.05M Tris-
HCl, pH 7.6; 0.01M MgCl2, 0.004M ATP) at 30uCf o r
60 min.
Figure 7. Prolonged Expression of MyHCemb in Postnatal Ozz
2/2 Mice. (A) Expression of MyHCemb in P7.5 null mutant and wild-type hind
limbs. Representative cross sections of the ozz null and wild-type m. gastrocnemius, showing a portion of fibula (Fi) bone and including a portion of
the intramuscular distal tendon (T), were stained with anti-MyHCemb and phalloidin. The right panels represent higher magnification pictures of the
areas boxed in yellow in the left panels. (B) Quantification of MyHCemb positive fibers in P7.5 null mutant and wild-type muscles. Data are expressed
as mean 6 SD of three independent experiments. Groups were compared by the Student t-test for two samples assuming equal variance. Mean
differences were considered statistically significant when P values were less than 0.05 (**).
doi:10.1371/journal.pone.0009866.g007
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MyHCemb fragment (used as control) or the ubiquination reaction
mixtures were diluted in 500 ml of RIPA buffer (50 mM Tris HCl
(pH 7.5), 150 mM NaCl, 1% NP–40, 0.1% deoxycholate, 0.1%
SDS, 1 mM EDTA, protease inhibitors and phosphatase inhib-
itors), immunoprecipitated with anti-MyHCemb (2B6), resolved on
a 7.5% SDS-gels, and immunoblotted with either anti-MyHCemb,
anti-ubiquitin, or anti-GST antibodies (Zymed).
Purification and In Vitro Ubiquitination of Native MyHC
Sarcomeric MyHC from P1 muscle was purified as described
[33,34]. Purified MyHC (3 mg) was subjected to in vitro
ubiquitination following the conditions described above. The
reaction mixtures were resolved on a 7.5% SDS-polyacrylamide
gel and immunoblotted with anti-ubiquitin antibody (Zymed).
Thin-Thick Filaments
Muscle sarcomeric thin-thick filaments were purified according
to the procedure of Trinick et al. [31].
Western Blotting
Protein concentrations were determined as OD 595, using
BSA as standard. 25 mgo fs o l u b l ep r o t e i no r6 . 2 5 mgo f
insoluble protein were electrophoresed (100 V, 60 min) on SDS-
gradient gels (NuPAGE 4–12% Bis-Tris Gel, Invitrogen), and
wet-blotted overnight at 30 mA. Membranes were probed with
specific antibodies at the dilutions listed above, followed by
HRP conjugated goat anti-rabbito ra n t i - m o u s eI g G( J a c k s o n
ImmunoResearch Laboratories). Signals were detected with a
West Femto maximum sensitivity substrate kit (Thermo
Scientific) on a molecular imager (ChemiDoc XRS, BioRad).
Each of the immunoblots included in the Figures was
representative of results obtained in at least three independent
experiments.
Immunoblots were photographed in a BioRad Chemidoc XRS
Molecular Imager, and, where appropriate, band densities
measured using BioRad Quantity One software. Montages were
assembled using Adobe Illustrator, and then converted to TIFF
files.
Figure 8. Model of the Sequence of Events Involved in Ozz-Mediated MyHCemb Degradation from Sarcomeric Thick Filaments. (A)
Ozz is bound to the rod portion of sarcomeric MyHCemb in the vicinity of residue 1535, a possible region for lateral binding with the ACD residues on
adjacent myosin rods [43]. Exchange between sarcomeric MyHCemb and newly synthesized neonatal MyHC may be initiated by full Ozz-E3 ligase
assembly and initiation of ubiquitination of sarcomeric MyHCemb, as demonstrated by co-immunoprecipitation of Ozz-Elo C from sarcomeric myosin,
and the presence of ubiquitinated MyHCemb in sarcomeric myosin preparations. (B) Isoform exchange, releasing soluble MyHCemb by now having a
full Ozz-E3 ligase assembled (C), leading to its prompt ubiquitination and proteolytic cleavage, resulting in the absence of Ozzylated MyHCemb in the
soluble myosin pool. (D) Further proteolytic degradation, involving specific proteases and ubiquitination of soluble fragments mediated by
monomeric ubiquitin ligases, e.g. MuRF family members.
doi:10.1371/journal.pone.0009866.g008
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Immunofluorescence analyses were performed on cultured
myotubes (day 4) treated and not treated with proteasome
inhibitor. MG-132 was added to the culture medium at a final
concentration of 5 mM for 6 hr at 37uC. Myotubes were fixed in
3% PFA and immunostained with anti-Ozz and anti MyHCemb
antibodies. Cy3 anti-rabbit IgG (Jackson Laboratories) and Alexa
Fluor 488 anti-mouse IgG (Invitrogen) were used as secondary
antibodies. Analysis of the fluorescence intensity of MyHCemb was
performed on cultured myotubes (day 4). In this experiment Cy3
anti-mouse IgG (Jackson Laboratories) was used as secondary
antibody.
Immunofluorescence analyses of MyHCemb expression in
muscle tissue were performed on hind limb muscles from wild-
type and ozz
2/2 P7.5 pups. Muscles were embedded in OTC
freezing solution and sectioned sequentially from the distal
tendinous insertion towards the mid belly region. Cross sections
were labeled with anti-MyHCemb and FITC-Phalloidin (SIGMA)
followed by incubation with Cy3-conjugated secondary antibody
(Jackson ImmunoResearch) prior to confocal microscopy imaging.
Images were acquired on a Nikon C1si confocal microscope,
with a Plan Apo 40X, NA 1.3 and/or Plan Apo 60X, NA 1.45
objective (Melville, NY).
Calculation of Co-localization Coefficients
Computational analyses of confocal images were performed
with the NES-Elements AR 3.1 (Melville, NY). Pearson’s
correlation coefficient (Rr), Manders overlap (R), and Manders
overlap coefficients k1 and k2 were employed to evaluate the
extent of co-localization of the two fluorescent dyes. Pearson’s
correlation coefficient (Rr) is one of the standard measures in
pattern recognition. It is used for describing the correlation of the
intensity distributions between channels. It takes into consideration
only similarity between shapes while ignoring the intensities of
signals. Its values range is between -1.0 and 1.0, where 1.0
indicates no overlap and 1.0 is a complete co-localization.
Manders overlap coefficient is a generally accepted measure of
co-localization. It indicates an overlap of the signals and thus
represents the true degree of co-localization. Values of the R are
defined from 0 to 1.0. If an image has an overlap coefficient equal
to 0.5, it implies that 50% of both its components overlap with the
other part of the image. A value of zero means that there are no
any overlapping objects Overlap coefficients k1 and k2 split the
value of co-localization into two separate parameters. k1 and k2
coefficients depend on the sum of the products of the intensities of
two channels. Thus, they are sensitive to the differences in the
intensity of two signals and should be used accordingly [41,42].
Statistical Analysis
Data were expressed as mean 6 SD and evaluated using
Student’s t-test for comparison with wild-type samples. Mean
differences were considered statistically significant when P values
were less than 0.05 (*).
Supporting Information
Figure S1 (A) Yeast 2-Hybrid Screen Demonstrating that Ozz
Interacts with the Tail Portion of MyHCemb (1047-1941 aa) but
not the Head and Neck (1-1041 aa).
Found at: doi:10.1371/journal.pone.0009866.s001 (8.67 MB TIF)
Figure S2 (A) Immunofluorescence analyses of the expression of
MyHCemb in ozz knock-out and wild-type differentiated myoblast
(day 4). (B) Quantification of intensity of the expression of
MyHCemb in the differentiated myoblast.
Found at: doi:10.1371/journal.pone.0009866.s002 (5.45 MB TIF)
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